High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts

SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedo...

Descripción completa

Detalles Bibliográficos
Autores principales: Naranbhai, Vivek, Chang, Christina C, Beltran, Wilfredo F Garcia, Miller, Tyler E, Astudillo, Michael G, Villalba, Julian A, Yang, Diane, Gelfand, Jeffrey, Bernstein, Bradley E, Feldman, Jared, Hauser, Blake M, Caradonna, Timothy M, Alter, Galit, Murali, Mandakolathur R, Jasrasaria, Rashmi, Quinlan, Joan, Xerras, Dean C, Betancourt, Joseph R, Louis, David N, Schmidt, Aaron G, Lennerz, Jochen, Poznansky, Mark C, Iafrate, A John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499676/
https://www.ncbi.nlm.nih.gov/pubmed/32906151
http://dx.doi.org/10.1093/infdis/jiaa579
Descripción
Sumario:SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM(+)IgG(+), 9.0% IgM(+)IgG(−), and 5.0% IgM(−)IgG(+)). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM(+)IgG(−). These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection.

Ejemplares similares